Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press
- CUNY’s report makes no findings of data manipulation.
- The “egregious misconduct” cited in the report relates to internal record-keeping failures at
- CUNY’s report finds that internal record-keeping failures “prevented us [
CUNY] from making an objective assessment” of research misconduct.
- Leak of
CUNYreport preceded by massive increase in short selling.
CUNY’s report makes no findings of data manipulation. Rather, the “egregious misconduct” cited in the report relates exclusively to internal record-keeping failures at
“We remain confident in the underlying science for simufilam, our lead drug candidate,” said
September 2023, Cassava Sciencesannounced the publication of new research that confirms the biological activity of simufilam. Researchers at the Cochin Institute( Paris, France) used a highly precise cell-based assay to show that simufilam interrupts amyloid binding to the α7 nicotinic acetylcholine receptor. Cassava Sciencesbelieves this protein interaction underlies simufilam’s mechanism of action in Alzheimer’s disease. The research appears in a special issue of International Journal of Molecular Sciences, a peer-reviewed scientific publication, and is currently available on-line at: https://www.mdpi.com/1422-0067/24/18/13927
May 2023, Cassava Sciencesannounced the publication of new data that highlights the biological activity of simufilam on Filamin A. Researchers at the University of Milan( Italy) showed a functional interaction between simufilam, filamin A (FLNA) and somatostatin receptors. Specifically, the researchers showed that simufilam treatment significantly reduced levels of phosphorylation at a site on FLNA in human pituitary tumor cells. The research was presented at the 25th European Congress of Endocrinologyand is currently available on-line at: https://www.endocrine-abstracts.org/ea/0090/ea0090oc7.5
February 2020, Cassava Sciencesannounced that filamin A inhibition by simufilam reduced seizure activity in a mouse model of epilepsy. The data was generated by researchers at Yale University, was published in Science Translational Medicine and is currently available on-line at: https://pubmed.ncbi.nlm.nih.gov/32075941/
Other independent researchers have shown a role for filamin A in neurodegeneration.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Cautionary Note Regarding Forward-Looking Statements:
This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: the continuation of our Phase 3 clinical program; results of research relating to simufilam and to the mechanism of action underlying simufilam; the treatment of patients with Alzheimer’s disease dementia; comments made by our employees regarding the purported
Simufilam is our investigational product candidate. Its safety, efficacy or science has not reviewed or approved by any regulatory authority in any jurisdiction and its desirable clinical attributes, if any, have not been established in patients.
Drug development involves a high degree of risk, and only a small number of research and development programs result in regulatory approval and commercialization of a product. Clinical results from our prior studies may not be indicative of results of future or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.
Such statements are based largely on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates, any unanticipated impacts of inflation on our business operations, and including those described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended
Source: Cassava Sciences, Inc.